FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885366885> ?p ?o ?g. }

• W2885366885 endingPage "780" @default.
• W2885366885 startingPage "771" @default.
• W2885366885 abstract "Women with complete androgen insensitivity syndrome (CAIS) after gonadectomy have complained about reduced psychological wellbeing and sexual satisfaction. The aim of this study was to compare the effectiveness of hormone-replacement therapy with either androgen or oestrogen in women with 46,XY karyotype and CAIS after gonadectomy.This national, multicentre, double-blind, randomised crossover trial was performed at three university medical centres and three specialised treatment institutions in Germany. Eligible participants were women aged 18-54 years with 46,XY karyotype, genetically diagnosed CAIS, and removed gonads. Participants were randomly assigned (14:12) by a central computer-based minimisation method to either oestradiol 1·5 mg/day for 6 months followed by crossover to testosterone 50 mg/day for 6 months (sequence A) or to testosterone 50 mg/day for 6 months followed by crossover to oestradiol 1·5 mg/day for 6 months (sequence B). Participants also received oestradiol or testosterone dummy to avoid identification of the active substance. All participants received oestradiol 1·5 mg/day during a 2 months' run-in phase. The primary outcome was mental health-related quality of life, as measured with the standardised German version of the SF-36 questionnaire. Secondary outcomes were psychological wellbeing, as measured with the Brief Symptom Inventory (BSI), sexual function, as measured with the Female Sexual Function Index (FSFI), and somatic effects, such as signs of virilisation and effects on metabolic blood values. The primary analysis included all patients who were available at least until visit 5, even if protocol violations occurred. The safety analysis included all patients who received at least oestradiol during the run-in phase. This trial is registered with the German Clinical Trials Register, number DRKS00003136, and with the European Clinical Trials Database, number 2010-021790-37.We enrolled 26 patients into the study, with the first patient enrolled on Nov 7, 2011, and the last patient leaving the study on Jan 23, 2016. 14 patients were assigned to sequence A and 12 were assigned to sequence B. Ten participants were withdrawn from the study, two of whom attended at least five visits and so could be included in the primary analysis. Mental health-related quality of life did not differ between treatment groups (linear mixed model, p=0·794), nor did BSI scores for psychological wellbeing (global severity index, p=0·638; positive symptom distress index, p=0·378; positive symptom total, p=0·570). For the FSFI, testosterone was superior to oestradiol only in improving sexual desire (linear mixed model, p=0·018). No virilisation was observed, and gonadotrophin concentrations remained stable in both treatment groups. Oestradiol and testosterone concentrations changed substantially during the study in both treatment groups. 28 adverse events were reported for patients receiving oestradiol (23 grade 1 and five grade 2), and 38 adverse events were reported for patients receiving testosterone (34 grade 1, three grade 2, and one grade 3). One serious adverse event (fibrous mastopathy) and 20 adverse events (16 grade 1 and four grade 2) were reported during the run-in phase, and 12 adverse events during follow-up (nine grade 1 and three grade 2).Testosterone was well tolerated and as safe as oestrogen for hormone-replacement therapy. Testosterone can be an alternative hormone substitution in CAIS, especially for woment with reduced sexual functioning.German Federal Ministry of Education and Research." @default.
• W2885366885 created "2018-08-22" @default.
• W2885366885 creator A5005005766 @default.
• W2885366885 creator A5008597202 @default.
• W2885366885 creator A5018333266 @default.
• W2885366885 creator A5034701397 @default.
• W2885366885 creator A5036719590 @default.
• W2885366885 creator A5040028217 @default.
• W2885366885 creator A5046700396 @default.
• W2885366885 creator A5049322494 @default.
• W2885366885 creator A5058827402 @default.
• W2885366885 creator A5060372793 @default.
• W2885366885 creator A5076963435 @default.
• W2885366885 creator A5078778513 @default.
• W2885366885 creator A5079817799 @default.
• W2885366885 creator A5085280704 @default.
• W2885366885 date "2018-10-01" @default.
• W2885366885 modified "2023-10-14" @default.
• W2885366885 title "Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial" @default.
• W2885366885 cites W1844869604 @default.
• W2885366885 cites W1917844282 @default.
• W2885366885 cites W1963824455 @default.
• W2885366885 cites W1970784464 @default.
• W2885366885 cites W1983017995 @default.
• W2885366885 cites W1994283699 @default.
• W2885366885 cites W1995659065 @default.
• W2885366885 cites W1998802321 @default.
• W2885366885 cites W2000366267 @default.
• W2885366885 cites W2001699213 @default.
• W2885366885 cites W2059479827 @default.
• W2885366885 cites W2064921386 @default.
• W2885366885 cites W2075896290 @default.
• W2885366885 cites W2079178946 @default.
• W2885366885 cites W2081338909 @default.
• W2885366885 cites W2112997260 @default.
• W2885366885 cites W2120385927 @default.
• W2885366885 cites W2121917893 @default.
• W2885366885 cites W2123823485 @default.
• W2885366885 cites W2139840896 @default.
• W2885366885 cites W2513836549 @default.
• W2885366885 cites W2562189250 @default.
• W2885366885 cites W2737813961 @default.
• W2885366885 cites W2757515646 @default.
• W2885366885 cites W2770165727 @default.
• W2885366885 cites W4243219641 @default.
• W2885366885 doi "https://doi.org/10.1016/s2213-8587(18)30197-9" @default.
• W2885366885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30075954" @default.
• W2885366885 hasPublicationYear "2018" @default.
• W2885366885 type Work @default.
• W2885366885 sameAs 2885366885 @default.
• W2885366885 citedByCount "32" @default.
• W2885366885 countsByYear W28853668852018 @default.
• W2885366885 countsByYear W28853668852019 @default.
• W2885366885 countsByYear W28853668852020 @default.
• W2885366885 countsByYear W28853668852021 @default.
• W2885366885 countsByYear W28853668852022 @default.
• W2885366885 countsByYear W28853668852023 @default.
• W2885366885 crossrefType "journal-article" @default.
• W2885366885 hasAuthorship W2885366885A5005005766 @default.
• W2885366885 hasAuthorship W2885366885A5008597202 @default.
• W2885366885 hasAuthorship W2885366885A5018333266 @default.
• W2885366885 hasAuthorship W2885366885A5034701397 @default.
• W2885366885 hasAuthorship W2885366885A5036719590 @default.
• W2885366885 hasAuthorship W2885366885A5040028217 @default.
• W2885366885 hasAuthorship W2885366885A5046700396 @default.
• W2885366885 hasAuthorship W2885366885A5049322494 @default.
• W2885366885 hasAuthorship W2885366885A5058827402 @default.
• W2885366885 hasAuthorship W2885366885A5060372793 @default.
• W2885366885 hasAuthorship W2885366885A5076963435 @default.
• W2885366885 hasAuthorship W2885366885A5078778513 @default.
• W2885366885 hasAuthorship W2885366885A5079817799 @default.
• W2885366885 hasAuthorship W2885366885A5085280704 @default.
• W2885366885 hasConcept C126322002 @default.
• W2885366885 hasConcept C134018914 @default.
• W2885366885 hasConcept C142724271 @default.
• W2885366885 hasConcept C187212893 @default.
• W2885366885 hasConcept C204787440 @default.
• W2885366885 hasConcept C27081682 @default.
• W2885366885 hasConcept C2775871022 @default.
• W2885366885 hasConcept C2777911890 @default.
• W2885366885 hasConcept C2779279991 @default.
• W2885366885 hasConcept C2779665388 @default.
• W2885366885 hasConcept C2780159708 @default.
• W2885366885 hasConcept C29456083 @default.
• W2885366885 hasConcept C71315377 @default.
• W2885366885 hasConcept C71924100 @default.
• W2885366885 hasConcept C87813604 @default.
• W2885366885 hasConceptScore W2885366885C126322002 @default.
• W2885366885 hasConceptScore W2885366885C134018914 @default.
• W2885366885 hasConceptScore W2885366885C142724271 @default.
• W2885366885 hasConceptScore W2885366885C187212893 @default.
• W2885366885 hasConceptScore W2885366885C204787440 @default.
• W2885366885 hasConceptScore W2885366885C27081682 @default.
• W2885366885 hasConceptScore W2885366885C2775871022 @default.
• W2885366885 hasConceptScore W2885366885C2777911890 @default.
• W2885366885 hasConceptScore W2885366885C2779279991 @default.
• W2885366885 hasConceptScore W2885366885C2779665388 @default.
• W2885366885 hasConceptScore W2885366885C2780159708 @default.

• next